Skip to main content
Signal8

PaxMedica, Inc. Common Stock (PXMD)

PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.

Sector: Biotechnology

Industry: Biotechnology

PaxMedica, Inc. Common Stock logo

PaxMedica, Inc. Common Stock

OTC:PXMDHealthcare
$0.0005
CLOSED
Mkt Cap$63K
EV-
Float10.69M
O/S126.26M
VOL759 sh
$ Vol$0
RVOL0.14×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
PaxMedica, Inc. Common Stock logoOTC:PXMDClosed$0.0005
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 10.69M · FMP free float

687
Oct 30 (18d)prev 687– 0.0%
1.00
Oct 30 (18d)prev 3.27▼ 69.4%
Borrow (IBKR)

The cost to borrow PXMD shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026687 sh
Oct 15, 2026687 sh
Sep 30, 2026687 sh
Sep 15, 2026687 sh
Aug 31, 2026687 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

Too few published sessions to show a reading in context.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for PXMD: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 687 PXMD shares were sold short (0.01% of a 10.69M-share float, 1.00 days to cover).